SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SAN FRANCISCO, Feb. 06, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in PixarBio Corporation (Other OTC:PXRB) to the March 27, 2017 Lead Plaintiff deadline in the securities class action lawsuit filed in the U.S. District Court for the District of New Jersey.
If you purchased PXRB securities (1) pursuant to PixarBio’s private placement that closed on October 30, 2016 or (2) on the open market between October 30, 2016 and January 20, 2017 (the “Class Period”) and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/PXRB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On January 3, 2017, PixarBio CEO Frank Reynolds disclosed the Company’s intent to acquire InVivo Therapeutics Holdings Corp. In response, InVivo stated it had never been involved in negotiations with PixarBio and rejected the offer.
Then, on January 23, 2017 the SEC froze trading of PixarBio shares and stated “the market for the security appears to reflect manipulative or deceptive activities.” Hagens Berman continues to investigate the SEC’s findings.
“We’re focused on the SEC’s ultimate determination of the matters warranting the trading halt and the damage inflicted on investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding PixarBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
